Loading
A phase 3 trial testing SHR-A1912 in diffuse large B-cell lymphoma, now recruiting.
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT06929624, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Open-label, Randomised Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Planned enrolment is 280 participants (estimated). The study started in 2025-04-24 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/